Trial Profile
A Single-arm, Open Label, Multi-center, Phase 2 Study of SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Patients Who Have Received Previous At Least Two Lines of Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms CAPTAIN
- Sponsors Jiangsu Hengrui Medicine Co.
- 01 Apr 2022 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Results assessing the efficacy and safety of camrelizumab in recurrent or metastatic nasopharyngeal carcinoma , presented at the 45th European Society for Medical Oncology Congress
- 19 Jun 2020 Planned End Date changed from 1 Mar 2020 to 30 Dec 2020.